1. Search Result
Search Result
Results for "

sirp-alpha-v2-cd172a-protein-human-aah38510-hek293-fc

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

5

Inhibitory Antibodies

41

Recombinant Proteins

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-143224B

    Others Cancer
    NCGC00138783 TFA is a selective inhibitor targeting CD47/SIRPα axis, with an IC50 of 50 μM. NCGC00138783 TFA directly blocks the interaction between CD47 and SIRPα axis .
    NCGC00138783 TFA
  • HY-P99533

    SRF-231; SRF231

    Interleukin Related Cancer
    Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction .
    Urabrelimab
  • HY-143224

    Others Cancer
    NCGC00138783 is a selective inhibitor targeting CD47/SIRPα axis, with an IC50 of 50 µM. NCGC00138783 directly blocks the interaction between CD47 and SIRPα axis .
    NCGC00138783
  • HY-115983

    Apoptosis Cancer
    DMUP is a potent CD47-SIRPα axis inhibitor. DMUP induces apoptosis and increases the macrophage phagocytosis in A549 cells. DMUP decreases the expression of CD47 and SIRPα protein. DMUP shows antitumor activity .
    DMUP
  • HY-143224A

    Others Cancer
    NCGC00138783 free base is a selective inhibitor targeting CD47/SIRPα axis, with an IC50 of 50 µM. NCGC00138783 free base directly blocks the interaction between CD47 and SIRPα axis .
    NCGC00138783 free base
  • HY-143225

    Others Others
    NCGC00538431 is a potent modulator of SIRPα-CD47 .
    NCGC00538431
  • HY-151132

    IsoQC-IN-1

    Others Cancer
    Glutaminyl cyclases-IN-1 (IsoQC-IN-1) is a potent glutaminyl cyclases (QC) inhibitor with IC50 values of 12 nM and 73 nM for human QC and isoQC, respectively. Glutaminyl cyclases-IN-1 can selectively interfere with the interaction of CD47/SIRPα through isoQC inhibition, and enhances the increased phagocytic activity of both THP-1 and U937 macrophages .
    Glutaminyl cyclases-IN-1
  • HY-16438
    RRx-001
    5+ Cited Publications

    Apoptosis Parasite Infection Inflammation/Immunology Cancer
    RRx-001, a hypoxia-selective epigenetic agent and studied as a radio- and chem-sensitizer, triggers apoptosis and overcomes agent resistance in myeloma. RRx-001 exhibits potent anti-tumor activity with minimal toxicity . RRx-001 is a dual small molecule checkpoint inhibitor by downregulating CD47 and SIRP-α . RRx-001 is a potent inhibitor of G6PD and shows potent antimalarial activity .
    RRx-001

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: